Midatech hopes to find golden touch with new focus
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Momenta starts countdown to biosimilars exit
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.